Short answer: With 2 mL of bacteriostatic water in a Cagrilintide + Semaglutide, 5 mg + 5 mg vial (5 mg Cagrilintide + 5 mg Semaglutide), every 10 units on a U-100 insulin syringe holds 250 mcg Cagrilintide and 250 mcg Semaglutide. The ratio is fixed, so you cannot change one peptide without changing the others. Amounts are arithmetic on the label, not dose advice.
This vial puts cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 medicine, together. The pairing is known as CagriSema from clinical trials. Research vials sold under this name are not the trial product, and the trial results say nothing about what is in a given vial.
The research vial most listings show is 5 mg + 5 mg (10 mg total), which is 1:1, the same ratio as the 2.4 mg + 2.4 mg weekly doses used in the trials. Check your label.
| Peptide | Commonly labeled | Share of vial | Guide |
|---|---|---|---|
| Cagrilintide | 5 mg | 50% | Cagrilintide guide |
| Semaglutide | 5 mg | 50% | Semaglutide guide |
The water volume changes how big each draw is, not what is in the vial. The highlighted row is 2 mL.
| Water added | Units in vial | Cagrilintide / 10 units | Semaglutide / 10 units |
|---|---|---|---|
| 2 mL | 200 | 250 mcg | 250 mcg |
| 3 mL | 300 | 166.7 mcg | 166.7 mcg |
| 5 mL | 500 | 100 mcg | 100 mcg |
| Units drawn | Volume | Cagrilintide | Semaglutide |
|---|---|---|---|
| 5 units | 0.05 mL | 125 mcg | 125 mcg |
| 10 units | 0.1 mL | 250 mcg | 250 mcg |
| 20 units | 0.2 mL | 500 mcg | 500 mcg |
| 30 units | 0.3 mL | 750 mcg | 750 mcg |
For any other vial, water volume or draw, the free peptide blend calculator does the same math for 2 to 5 peptides.
mg of that peptide ÷ mL of water. For Cagrilintide + Semaglutide, 5 mg + 5 mg with 2 mL: Cagrilintide 5 ÷ 2 = 2.5 mg/mL, Semaglutide 5 ÷ 2 = 2.5 mg/mL.amount ÷ its concentration = mL. Example: 250 mcg of Semaglutide is 0.25 ÷ 2.5 = 0.1 mL.mL × 100 on a U-100 syringe: 0.1 × 100 = 10 units.mL × concentration for each other peptide: 250 mcg Cagrilintide.A blend is one solution, so every draw takes the same share of each peptide. In the example above, drawing 10 units for 250 mcg of Semaglutide also gives 250 mcg Cagrilintide. Doubling the draw to 20 units doubles all of them, to 500 mcg Cagrilintide. There is no draw that changes one peptide and leaves the others where they are.
More or less water does not help either: it changes how many units each draw is, not the ratio between the peptides. If you need to set the amount of each peptide on its own, they have to be in separate vials (a stack), each with its own single-peptide calculation.
Unlike most blends, this combination has been tested in people, as an investigational product given once weekly under the skin. A phase 1b trial in 96 people raised cagrilintide doses alongside semaglutide 2.4 mg. The 68-week phase 3a REDEFINE 1 trial in 3,417 adults without diabetes reported an estimated mean body-weight change of -20.4% with cagrilintide 2.4 mg + semaglutide 2.4 mg versus -3.0% with placebo; gastrointestinal adverse events affected 79.6% versus 39.9%. These trials did not use research vials, and their results do not tell you the content or purity of one. [1][2]
Below is what is published for each peptide. "Amounts studied" are what a study gave or reported, often by a different route; they are not personalized advice. Confirm anything about your own use with your prescriber.
Not FDA approved: we found no approval for cagrilintide in FDA's Drugs@FDA database (checked October 2026). It is a long-acting amylin analogue that has been tested in people together with semaglutide (see the combination section on this page). [1][2]
Amounts studied: Once weekly under the skin: 0.16 to 4.5 mg alongside semaglutide 2.4 mg in a phase 1b trial (96 people), and 2.4 mg alongside semaglutide 2.4 mg in the 68-week phase 3a REDEFINE 1 trial. In both, doses were raised step by step over several weeks.
FDA compounding list: On FDA's page of bulk drug substances that may present significant safety risks in compounding, cagrilintide is not listed (checked October 2026). [3]
FDA approved, as OZEMPIC (including for blood sugar control in adults with type 2 diabetes) and as WEGOVY (including for weight reduction in people with obesity, or overweight with a weight-related condition). A research vial mixed with another peptide is not one of the approved products. [4][5]
Amounts studied: The approved labels set the doses for each product and use. In the cagrilintide trials on this page, semaglutide was given at 2.4 mg once weekly under the skin.
Regulatory status. Semaglutide is FDA approved (OZEMPIC, WEGOVY). Cagrilintide is not: we found no approval for cagrilintide or a cagrilintide + semaglutide product in Drugs@FDA as of October 2026. A research vial with both is not an approved product. [4][5]
Blend compositions were checked against several retail product listings in October 2026. We do not name or link sellers.